Penthrox approved in Sweden, Norway, Poland and Croatia
27 March 2018 ASX Announcement Penthrox approved in Sweden, Norway, Poland and Croatia Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Sweden, Norway, Croatia and Poland. For the full release please refer to the following link:?ASX Announcement – Penthrox approved in Sweden, Norway, Poland and […]
Read moreCEO Roadshow Presentation
26 February 2018 ASX Announcement Please refer to the attached link for the latest version of the CEO Roadshow Presentation – Road Show March 2018 – MVP
Read moreStage II success for new manufacturing technology – Lidocaine
20 February 2018 ASX ANNOUNCEMENT ?Stage II success for new manufacturing technology: Lidocaine Medical Developments International Limited (ASX: MVP) is delighted to announce that, in partnership with the CSIRO, it has successfully completed a small-scale production run for Lidocaine using MVP?s new manufacturing technology. Lidocaine has worldwide sales of approximately $3.4 billion. It is a […]
Read moreFirst Penthrox order received for Austria
19 February 2018 ASX Announcement Penthrox : First order received for Austria Medical Developments International Limited (ASX: MVP) is delighted to announce that it has received its first order for Penthrox for launch in Austria. The Marketing Authorisation for Austria was received and announced on 29 January 2018. The company is expecting other orders to […]
Read morePenthrox approved in Estonia
19 February 2018 ASX Announcement Penthrox approved in Estonia Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Estonia. The Republic of Estonia Agency of Medicines issued the Marketing Authorisation on 13 February 2018. For the full announcement, please refer to the following link -?ASX Announcement […]
Read moreMVP – Half Year Report and Accounts
16 February 2018 HALF-YEAR REPORT Pursuant to listing rule 4.2A, please find following Medical Developments International’s Consolidated Half-Year Report and associated results announcement, which should be read in conjunction with the most recent annual financial report. For a full copy of the Half-Year Report, please click on the following link:?FY18 HY Results
Read moreMVP signs major deal with Walgreens in the USA
12 February 2018 ASX ANNOUNCEMENT MVP signs major deal with Walgreens in the USA Medical Developments International Limited (ASX: MVP) is delighted to announce that it has finalised a ?Ranging? deal with Walgreens in the USA. Walgreens is the second-largest pharmacy store chain in the United States with almost 9,000 stores. It is a subsidiary […]
Read morePenthrox approved in Austria
29 January 2018 ASX Announcement Penthrox approved in Austria Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Austria. The Austrian Medicines Agency issued the Marketing Authorisation on 19 January 2018. For the full release please refer to the following link – ASX Announcement – Penthrox […]
Read morePenthrox approved in Iceland
22 January 2018 ASX Announcement Penthrox approved in Iceland Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Iceland. The Icelandic Medicines Agency issued the Marketing Authorisation on 16 January 2018 making Penthrox available for sale effective immediately. For the full announcement, please refer to the […]
Read moreASX Announcement: Penthrox approved in another 22 European countries
12 December 2017 ASX Announcement Penthrox approved in another 22 European countries Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for use in an additional 22 European countries today, further underwriting the confidence that global health authorities have in our dossier. The Medicine and Healthcare products Regulatory Agency […]
Read more